Dr. Michael Thomas Byrne, DO

Dr. Byrne practices at Tennessee Oncology in Chattanooga, Tennessee.

Dr. Byrne's NPI, 1316112634, was assigned on April 28, 2008. Dr. Byrne graduated from LECOM at Seton Hill - Greensburg in 2007. Dr. Byrne holds Tennessee license DO2910.

Dr. Byrne's primary practice is Tennessee Oncology, at 605 Glenwood Dr, Chattanooga, TN 37404 in Hamilton County. The practice phone is (615) 329-0570.

Dr. Byrne's primary practice is Tennessee Oncology in Chattanooga, Tennessee. Dr. Byrne is also affiliated with Ascension Saint Thomas Hospital West. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Byrne to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Byrne practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Byrne's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Byrne is board certified in 2020 - 2025 by the AL State License. Dmand AI has Dr. Byrne's licenses on file in 4 states: Tennessee, California, Florida and Ohio.

Dmand AI lists lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Byrne treats.

CMS data shows 2,649 Medicare services from Dr. Byrne across 18 procedure codes in 2024, for 147 Medicare patients. Medicare paid $87,603 for them.

CMS counts 147 Medicare patients who saw Dr. Byrne in 2024. The largest group is 65 to 74, with 74 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Byrne's median patient age at 69, with 49% women.

In 2024, Dr. Byrne wrote 793 Medicare Part D claims for 91 patients. 75% of them were for generic drugs. CMS names the drug for 581 of them, across 19 drugs with 11 or more claims each, at $1,575,575 in total drug cost. In 2023, CMS named 106 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Byrne for performance year 2024, reported as part of a group. Dr. Byrne accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Byrne as offering telehealth.

Dmand AI links 96 papers to Dr. Byrne, published from 2007 to 2025. 2018 was the busiest year, with 8. The most frequent topics are Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute and Graft vs Host Disease. Dr. Byrne has published most often in Bone Marrow Transplant. Dr. Byrne's most frequent co-authors are Brian G. Engelhardt, MD, Adetola A. Kassim, MD and Madan Harikishin Jagasia, MD.

Dmand AI links Dr. Byrne to 8 clinical trials, 4 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Anemia, Refractory, with Excess of Blasts, Disease Attributes and Graft vs Host Disease. Bellicum Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Byrne that name 1 trial.

CMS Open Payments shows 58 general payments to Dr. Byrne from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Kite Pharma, Inc. paid the most, $6,949. It also lists 3 research payments totaling $5,743 in 2021, naming 1 clinical trial.

Dmand AI lists 6 awards for Dr. Byrne, most recently ASH Travel Award in 2013. Dr. Byrne serves on UCSF Early Phase Site Committee and UCSF Fellowship Program Steering Committee.

Dr. Byrne graduated from LECOM at Seton Hill - Greensburg in 2007. Dr. Byrne is a member of AACR, AOA, American Society of Blood and Marrow Transplantation, ASCO and ASH.

Dr. Byrne is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.